Alnylam Pharmaceuticals ALNY Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's interest expense?
- Alnylam Pharmaceuticals (ALNY) reported interest expense of $82.05M in Q2 2026.
- How has Alnylam Pharmaceuticals's interest expense changed year-over-year?
- Alnylam Pharmaceuticals's interest expense increased by 103.9% year-over-year, from $40.25M to $82.05M.
- What is the long-term trend for Alnylam Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's interest expense has grown at a 9.9% compound annual growth rate (CAGR), from $143.02M to $208.35M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.